- Senior Investigator, Laboratory of Cell Biology
Dr. Gottesman obtained his M.D. from Harvard University Medical School, completed his internship and residency in medicine at the Peter Bent Brigham Hospital in Boston, and received his postdoctoral research training in molecular genetics with Martin Gellert at the NIH. After a year as an assistant professor in the Department of Anatomy at Harvard, he moved to the NIH in 1976. He currently serves as the NIH deputy director for intramural research as well as chief of the Laboratory of Cell Biology.
- (1981). INVITRO ASSEMBLY OF HOMOPOLYMER AND CO-POLYMER FILAMENTS FROM INTERMEDIATE FILAMENT SUBUNITS OF MUSCLE AND FIBROBLASTIC CELLS. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 78(6), 3692-3696.
- (2020). Inhibition of glutathione peroxidase mediates the collateral sensitivity of multidrug-resistant cells to tiopronin (vol 289, pg 21473, 2014). JOURNAL OF BIOLOGICAL CHEMISTRY. 295(13), 4370-4370.
- (2020). A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer. EXPERIMENTAL CELL RESEARCH. 388(2),
- (2020). Collateral Sensitivity of Multidrug-Resistant Cells to the Orphan Drug Tiopronin (Retraction of Vol 54, Pg 4987, 2011). JOURNAL OF MEDICINAL CHEMISTRY. 63(3), 1443-1443.
- (2020). Mycoplasma Infection Mediates Sensitivity of Multidrug-Resistant Cell Lines to Tiopronin: A Cautionary Tale. JOURNAL OF MEDICINAL CHEMISTRY. 63(3), 1434-1439.
- (2020). The Evolving AML Genomic Landscape: Therapeutic Implications. CURRENT CANCER DRUG TARGETS. 20(7), 532-544.
- (2019). Coexpression of ABCB1 and ABCG2 in a Cell Line Model Reveals Both Independent and Additive Transporter Function. DRUG METABOLISM AND DISPOSITION. 47(7), 715-723.
- (2019). Heterogeneity in refractory acute myeloid leukemia. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 116(21), 10494-10503.
- (2019). Model systems for studying the blood-brain barrier: Applications and challenges. BIOMATERIALS. 214,
- (2019). Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells. CANCER LETTERS. 457, 110-118.